It’s been a big week for Valeant Pharmaceuticals International (VRX). The troubled drug maker released estimate-beating third quarter financial results earlier this week that had many, even some of the biggest bears on the stock, commending the headway Valeant has made in streaming the company, fixing its balance sheet and getting new drugs approved. Getty Images The market has […]